These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 17279542)

  • 1. Acute dystonia after injection of pegylated interferon alpha-2b.
    Quarantini LC; Miranda-Scippa A; Parana R; Sampaio AS; Bressan RA
    Mov Disord; 2007 Apr; 22(5):747-8. PubMed ID: 17279542
    [No Abstract]   [Full Text] [Related]  

  • 2. Ecstasy and acute dystonia.
    Cosentino C
    Mov Disord; 2004 Nov; 19(11):1386-7; author reply 1387. PubMed ID: 15390124
    [No Abstract]   [Full Text] [Related]  

  • 3. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y; Kanto H; Itoh M
    J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous necrosis complicating the injection of pegylated interferon alpha-2b in a patient with chronic hepatitis C.
    Rosina P; Girolomoni G
    Acta Dermatovenerol Croat; 2008; 16(1):35-7. PubMed ID: 18358108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.
    Dalmau J; Pimentel CL; Puig L; Peramiquel L; Roé E; Alomar A
    J Am Acad Dermatol; 2005 Jul; 53(1):62-6. PubMed ID: 15965422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Devices for the safe performance of self-injection of interferon therapy for chronic hepatitis C].
    Kurihara T; Mikata R; Yokosuka O
    Nihon Rinsho; 2006 Jul; 64(7):1368-73. PubMed ID: 16838658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Chen YC; Lu SN; Lin MC
    Chang Gung Med J; 2007; 30(1):92-7. PubMed ID: 17477035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute pancreatitis attributed to the use of pegylated interferon in a patient with chronic hepatitis C.
    Tahan V; Tahan G; Dane F; Uraz S; Yardim M
    J Gastrointestin Liver Dis; 2007 Jun; 16(2):224-5. PubMed ID: 17592576
    [No Abstract]   [Full Text] [Related]  

  • 9. A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C.
    Krawitt EL; Gordon SR; Grace ND; Ashikaga T; Ray MA; Palmer M; Yarze JC; Moskowitz S;
    Am J Gastroenterol; 2006 Jun; 101(6):1268-73. PubMed ID: 16771948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C.
    Annicchiarico BE; Siciliano M
    Aliment Pharmacol Ther; 2004 Jul; 20(1):123-4; author reply 124. PubMed ID: 15225179
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C.
    Thomas WL; Ramos F; Hospenthal DR
    Hawaii Med J; 2003 Aug; 62(8):163-4. PubMed ID: 14533347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injection site with generalized rash caused by pegylated interferon alpha 2a injection.
    Kawada K; Maeda N; Kobayashi S; Sowa J; Tsuruta D; Kawada N
    Dermatology; 2006; 212(1):82-3. PubMed ID: 16319482
    [No Abstract]   [Full Text] [Related]  

  • 13. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Santin M; Shaw E
    Lancet; 2002 Jan; 359(9302):263; author reply 264. PubMed ID: 11812596
    [No Abstract]   [Full Text] [Related]  

  • 14. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Cecil BD
    Lancet; 2002 Jan; 359(9302):263-4. PubMed ID: 11812598
    [No Abstract]   [Full Text] [Related]  

  • 15. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Picon PD; Costa AF; Kuchenbecker R; Beltrame A
    Lancet; 2002 Jan; 359(9302):263; author reply 264. PubMed ID: 11812597
    [No Abstract]   [Full Text] [Related]  

  • 16. [Current trends and first clinical studies of therapy for chronic hepatitis C in children using pegylated interferon alpha and ribavirin].
    Słuzewski W; Mozer-Lisewska I; Figlerowicz M; Kowala-Piaskowska A; Słuzewska M
    Przegl Epidemiol; 2005; 59(2):595-9. PubMed ID: 16190571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
    J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local blistering reaction complicating subcutaneous injection of pegylated interferon in a patient with hepatitis C.
    Gallina K; Brodell RT; Naffah F; Nedorost S
    J Drugs Dermatol; 2003 Jan; 2(1):63-7. PubMed ID: 12852384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon alfa-2b (peg-intron) plus ribavirin (rebetol) in the treatment of chronic hepatitis C: a local experience.
    Seow EL; Robert Ding PH
    Med J Malaysia; 2005 Dec; 60(5):637-41. PubMed ID: 16515116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
    Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
    J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.